Notes

The Catalyst fund is for research only and is not eligible. A panel is not an approval, so we will compare links with prior notes. On September 8, 2026, at 19:00:50 UTC, a source from the FDA website was checked. The status was 200, and the date text was present, but there were no matching links. The fund size is 0. On July 28, 2026, SFIX filed a report with the SEC. On June 15, 2026, LOVE filed a report with the SEC. An RSS feed from LOVE announced a second-quarter conference call on August 27, 2026. Reviews of LOVE and SFIX are scheduled: LOVE on September 10 at 12:30 UTC, and SFIX on September 24 at 12:30 UTC. The rules are to monitor cash and growth, and to stay in cash if there are any issues. No automatic orders will be placed. This is not an exhaustive list.

The fund is called Catalyst Research and its size is 0 as of September 8, 2026, at 17:16:02 UTC. A news scan found the headline 'Telix Completes Enrollment in Phase 3 BiPASS' on September 1, 2026, at 22:25:55. Another news scan found the headline 'Mission Produce to Release Fiscal Third Quarter' on August 25, 2026, at 16:05:27. ABM reported its fiscal third quarter 2026 results on September 8, 2026, at 06:58:07. Roivant announced positive results from the PHocus study on September 8, 2026, at 06:00:31. The SEC website has a filing for UNFI on September 8, 2026. Roivant's earnings were reviewed on September 8 at 10:30 UTC, with a call at 12 UTC. The PHocus study had primary and secondary endpoints, including PVR and 6MWD, which were compared for cutoff, N, missingness, and safety. There was no run-up session. The earnings schedule includes ABM and UNFI in the morning on September 8, and AVO after close on September 8, with reviews at 12:30 UTC on September 8 for ABM and UNFI, and on September 9 for AVO. The goal for TLX is September 11, but earlier decisions are possible. The macro schedule includes QFR at 14 UTC, SCE at 15 UTC, and credit at 19 UTC on September 8, and ECEC and QSS at 14 UTC on September 9. The agency URLs and periods are in the observations from September 7, numbered 8967-8972. All branches follow these rules: if the outcome is favorable, record the full primary data and require an independent net edge; if the outcome is adverse, delayed, or absent, go to cash and reverify the date. No orders are made. The job ends with 4 RSS and 1 SEC, and includes static reminders that are not exhaustive.

A news scan found the headline was not necessary for this report. On September 8, a lunch audit was completed at 16:34 UTC, which was within the 39-minute plan and 45-minute hard limit. The audit found $49.14 in cash, with no open, pending, or closing positions. There were 20 owned positions, but none were armed, and 5 active jobs. Analyses from 1214 to 1217 and observations from 15850 to 15854 showed that a new 8K report from MIRM, available at https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm, reported a Chief Medical Officer transition expected on September 21, which is related to employment, not an FDA result. A full retrieval of sources from the Edgar document was successful. An AVO notice from August 25 was still active at 16:31 on September 8, after the close at 17 ET. The frozen position had a mean of -1.2125949646%, and the quarter Kelly was 0, which is a measure of the optimal fraction of a portfolio to invest in a stock. No quotes or retests were needed. The next check was scheduled for 19:40, with actual jobs 52 and 80 scheduled for 17:15 and 18:45, respectively. Jobs 48, 67, and 80 were completed at 20 UTC, 00:30 on September 9, and 14:45, respectively. A GIS issuer conference was held on September 8 at 19 UTC, and the source is available at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Remarks-at-Barclays-Global-Consumer-Staples-Conference-on-Sept--8-2026/default.aspx. The chosen review at 19:40 was an unarmed static reminder to verify actual remarks and cash guidance, either way, and the frozen GIS stress holdout was negative. Another review was scheduled for September 9 at 12:30, which was also an unarmed job reminder to monitor capital at 20, with a flat book and no automatic entry. Positive updates require an independent costed edge, which means a trading advantage that is calculated independently. Adverse, delayed, or absent updates require retaining cash and re-verifying primary information. The earliest owned armed position was CHWY on September 12 at 12 UTC, and no other fund monitors were resolved. It is important not to treat headline leads as primary evidence, but rather to verify information through other sources.

The trading audit started with $49.14 in cash. The goal is to achieve repeatable net gains before events, with a validated expectancy as the binding constraint. Since all previously recorded entry rules failed, recovery pressure was set aside. A proposal for resolution is eligible before the next run at 19:40 UTC. Intraday moves and analyst opinions are considered noise without a validated rule. The decision tree includes: 1. Has the primary evidence changed? This includes checking if there are new filings from MIRM, such as actual event dates versus filing dates, and clinical or regulatory content versus corporate content. It also involves looking at AVO for early results and altered dates, and FDA collectors for early decisions and full-pipeline risks. 2. Is there an existing edge? This involves reviewing the frozen test, including costed holdout and notice-aware entry window, live record, including censored operator exits and stop gaps, and size, including quarter Kelly and $49.14 capital with $8.50 risk and whole shares. 3. Is there off-run coverage? This includes checking the ledger for open and pending items, monitors for due and unarmed reminders, and jobs for actual complete outputs and next execution versus scheduled timestamp. Lessons 412 through 414 apply to this process. No new parameter search will be conducted during the trading audit. A news scan found the headline is not applicable in this context, this is a trading audit report.

The fund is called Catalyst Research and it has no size. The current time is 2026-09-08T16:30:39.354389+00:00 UTC. There are updates on three stocks: SRRK, SCHL, and PRAX. SRRK is Scholar Rock, which received FDA Fast Track Designation on September 2, 2026. It also presented at an investor conference on August 27, 2026, and provided an update on apitegromab on August 21, 2026. SCHL is Scholastic Corporation, which announced its first quarter fiscal 2027 date on September 3, 2026. PRAX is Praxis Precision Medicines, Inc., which announced inducement grants on September 3, 2026. There is also an SEC filing for SRRK on August 6, 2026. The fund will review SRRK on September 9, 12:00 UTC, September 10, 13:20 UTC, and September 29, 12:30 UTC, before the PDUFA date on September 30. SCHL will have a release on September 24, 16:00 ET, and will be reviewed on September 25, 12:30 UTC. PRAX will replace its current information on December 27, and had an SEC filing on June 29. The fund's decisions are based on either favorable data, which leads to recording and independent validation, or adverse, delayed, or absent data, which leads to cash or re-verification. There is no automatic entry and static reminders are not exact execution times. The fund has 3 SRRK, 1 SCHL, and 1 PRAX, and 1 SEC filing, but this is not an exhaustive list.

The Catalyst fund is researching IONS, MIRM, and GIS, with a size of 0, as of September 8, 2026, at 16:00:41 UTC. The fund reviewed SEC filings for IONS on September 4, 2026, MIRM on September 8, 2026, and GIS on July 1, 2026. A news scan found the headline 'Why Is Eli Lilly Stock Falling Tuesday?' on September 8, 2026. The fund also noted a conference start on September 8, 2026, at 19:00 UTC, and a scheduled earnings report for GIS on September 23, 2026. The fund's strategy is to either review improving organic volume or cash and guidance, or retain cash if the information is weak or delayed. The baseline for GIS is a fiscal year 2027 EPS of 3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of 750 million. The fund will verify actual releases and biotech pipelines, with no automatic trades. This review is not exhaustive and includes 3 filing checks, 1 headline lead, and 2 GIS reminders.

The Catalyst fund is for research only and is not eligible. A panel is not an approval. The system compared links with prior notes. On September 8, 2026, at 14:45:35 UTC, the system checked the FDA website at https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting. The system found a status of 200, which means the request was successful, and the date text was present, but there were no matching links. The system also checked the SEC filings for SFIX on July 28, 2026, at https://www.sec.gov/Archives/edgar/data/1576942/000162828026050133/sfix-20260722.htm and for LOVE on June 15, 2026, at https://www.sec.gov/Archives/edgar/data/1701758/000121390026068869/ea0294793-8k_lovesac.htm. Additionally, the system checked the LOVE RSS feed, which announced a second-quarter conference call on August 27, 2026. The system chose to review LOVE on September 10 at 12:30 UTC and SFIX on September 24 at 12:30 UTC. The system will monitor cash and organic growth, and require independently validated net events. If there are adverse or early events, the system will stay in cash and reverify the primary date. There are no automatic orders.

On September 8 at 13:50, a trading run showed the fund had $49.14 in cash, with no open, pending, or closing positions, and 20 armed jobs with none due. There were 5 active jobs and no proposals. The AVO date after close was reverified today, and the newest RSS notice was from August 25. The source of this information is https://investors.missionproduce.com/rss/news-releases.xml. The cost of frozen positions was -1.2125949646% on average, and the quarter Kelly was 0. At 13:52, IEX observations showed a range of 15827-15832, with ROIV last at 40.865, which is a 16.94% increase from the prior IEX observation. The prices for AVO were 12.65 and 12.68, and the spreads for ABM, UNFI, and CAN were 23-29%. The SIP was 403. These observations are prospective evidence and not official open or NBBO quotes, and they do not assume fills. The next inspection will be at 16:30 to review actual job performance, including job 80 at 14:30, job 48 at 15:45, and job 67 at 16:15. Job 52 was completed at 13:15 and will be reviewed again at 17:15. The AVO review on September 9 at 12:30 remains static and unarmed, meaning it is not ready for execution. The existing own CHWY monitor is set for September 12 at 12 UTC, and other fund due monitors should not be resolved. The new primary evidence has improved, so it will be recorded and an independent net rule will be required. If the evidence is adverse, delayed, or absent, the cash will be retained, the issuer will be reverified, and no delay will be inferred from a failed index. No extra jobs or monitors are necessary for a flat book, and there are named gaps in strategy analysis. The repro script research/audit.py and snapshots.json local have been reviewed, and no new backtest or retuning is necessary for this trading run.

The trading fund started with $49.14 in cash, aiming for repeatable net pre-event returns. The main constraint is an independently validated expectancy. Since all previous entry rules failed, recovery pressure was set aside. A new proposal is eligible for review before 16:30 UTC, excluding intraminute noise. The decision tree has three main parts: 1. New evidence, including AVO timing, morning releases, and FDA decisions. 2. Assessing if evidence supports risk, using frozen tests, live history, and venue analysis. 3. Off-run coverage, including ledger, monitors, and collectors. Lessons 391-393 are applied, meaning no retuning of failed run-ups, inspecting RSS delivery, and quarterKelly0 means cash. The trading run uses already recorded tests, without searching for a new broad strategy.

The fund is called Catalyst Research and its size is 0. The time is 2026-09-08T13:15:35.178505+00:00. A news scan found the headline 'Telix Completes Enrollment in Phase 3 BiPASS' on September 1, 2026, which is about a clinical trial, a medical research study. A news scan also found the headline 'Mission Produce to Release Fiscal Third Quarter' on August 25, 2026. Another news scan found the headline 'ABM Reports Fiscal Third Quarter 2026 Results' on September 8, 2026. Additionally, a news scan found the headline 'Roivant Announces Positive Results from PHocus' on September 8, 2026, which is about a medical study. The company UNFI filed a report with the SEC, a government agency that regulates companies, on September 8, 2026. The company ROIV will have an earnings report on September 8 at 10:15 UTC and a conference call at 12:00 UTC. The first news about this may be released earlier. The PHocus study has two main goals, PVR and 6MWD, which are medical terms for measuring patient outcomes. The earnings reports for ABM and UNFI will be released on the morning of September 8, and for AVO after the market closes on the same day. The reviews of these reports will be done at 12:30 UTC on September 8 for ABM and UNFI, and at 12:30 UTC on September 9 for AVO. There are also macroeconomic events scheduled, including the release of QFR at 14:00 UTC and SCE at 15:00 UTC on September 8, and ECEC and QSS at 14:00 UTC on September 9. The company will make decisions based on these reports and events. If the results are favorable, the company will record the primary data and require an independent net edge, which means a profit. If the results are adverse, delayed, or absent, the company will move to cash and reverify the date. The company never places orders. The information is based on 4 RSS feeds and 1 SEC filing, and includes static reminders, but is not exhaustive.

A trading audit was completed within the 30-minute plan and 45-minute maximum. Research stopped at 12:34:40 UTC and the reserved record phase was used next. The catalyst had 49.14 cash, zero open or queue items, and 20 armed monitors with none due. There were no proposals. An existing job, number 52, will collect data on ROIV, AVO, and ABM, plus UNFI SEC, at 13 UTC and verify actual output at 13:50, which is not a delivery time. Other jobs, numbers 48, 67, 75, and 80, will retain coverage, and no new job or monitor is needed to support zero exposure, with 5 job and 20 monitor caps acknowledged. AVO, or average volume, will be checked after the close on September 8, with a source at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial. An existing job, number 52, has a reminder for September 9 at 12:30, which is not an exact execution time, and is unarmed. At 13:50, any changed dated news will be checked and prospective reactions will be recorded, but favorable fundamentals need an independent costed post-event strategy, and negative or delayed news will result in retaining cash and re-verifying. The freshest source for CAN, or Canaan, is an RSS feed at https://investor.canaan-creative.com/rss/news-releases.xml, which was tested using the CLI rss fetch command. The correct indexes for ABM, ROIV, and CAN are /news-events/press-releases, /news-events/press-releases, and /news-events/news-releases, respectively. Initial indexes at /news-releases were incorrect and resulted in 404 errors, indicating wrong paths, not a lack of news. Files research/check.py, results.py, and derived.json hold repro checks locally. For INBX 15771, there was a spacing clarification, with an expansion of CPS, or clinical per patient score, of greater than or equal to 1, and 5 patients were excluded from the evaluable analysis, which had 68 randomized patients minus 63, and was not CPS greater than or equal to 1.5. Full ITT, or intent to treat, decks, SAP, and financing, as well as exact ABM, UNFI, and INBX first release minutes, and unvalidated post-event payoffs, are named gaps. All past tests are frozen, and no fresh quotes or retests will be spent on rejected entries. A monitor for CHWY is owned and will be checked on September 9 at 12 UTC, but other funds' monitors have not been resolved.

A tool's clock showed 12:33:52 UTC, which is 3 minutes and 10 seconds earlier than previously thought. Earlier comments had rounded the time upward. An observation, numbered 15738, was estimated to have been fetched around 12:35 UTC, but this was incorrect. The CAN RSS fetch actually happened before 12:33:44 UTC. The correct time for the retrieval is between 12:32 and 12:33:44 UTC. The source release time of 06:30 ET remains unchanged. It is important to use the precise server timestamps instead of estimates. New releases of ABM and CAN were found after looking past a stale index and a 404 path, and there was no delay.

The trading fund manager started with $49.14 in cash and a goal to achieve repeatable pre-event net base hits, with a binding constraint of a numeric validated edge. The manager had to set aside the desire to recover $349.01, as all recorded entry rules were rejected prior to this. The decision was made to place an eligible order before the next 13:50 UTC run, as analyst target changes and intraminute noise do not establish an edge, which refers to a small advantage in trading. A question tree with three levels was used to guide the decision-making process. The first level considered whether new primary evidence changed eligibility, including ROIV readout, which is a measure of return on investment, and its first release versus call, endpoint population, and safety. The second level considered whether existing evidence authorized a trade, including frozen strategy, which is a set of predefined rules, and live record, which refers to the actual performance of the trading system. The third level considered whether off-run coverage was sufficient, including holdings and orders, monitors, and jobs. The manager prioritized the least predictable new disclosures first and did not retest failed rules simply because prices moved. The manager also applied lessons 385, 386, and 387, which state that an expired entry stays expired, RSS delivery must be verified, and a zero Kelly, which is a measure of the optimal bet size, means zero sizing, or not placing a trade.

The fund, which is called Catalyst Research, made some notes on September 8, 2026, at 12:16:02 UTC. The notes mention two companies that filed reports with the Securities and Exchange Commission, or SEC, which is a government agency that regulates companies. The first company, High Tide, filed a report on August 31, 2026, and the second company, Biofrontera, filed a report on August 13, 2026. There is also a news article about Dave & Buster's Entertainment, Inc., which is a company that owns restaurants and entertainment centers, and it will report its second quarter results on September 1, 2026. The notes also mention several other companies, including TSM, DATA.L, ET.TO, GIS, NKE, CAN, PLAY, ABVX, EGTX.ST, and 4431.T, and their respective report dates and times. The notes explain that the fund will review these reports and make decisions based on the information, but it will not make any automatic orders. The fund also mentions that it rejected a proposal to buy or sell shares of PLAY because the potential profit was not high enough, with a confidence interval of -4.48% to 7.25%. The notes also mention that the fund is monitoring EGTX, a company that is waiting for a decision from the FDA, which is a government agency that regulates food and drugs, on September 28, 2026. The fund has chosen to review EGTX on September 11 and 16, and again on September 25, before the FDA decision. If EGTX gets a new label or positive results from a clinical trial, the fund will record and validate the information, but if the results are adverse or delayed, the fund will stay in cash and reverify the information. The fund also mentions that it has a 50% net edge, which means it expects to make a 50% profit, and a static reminder, which is a reminder that is not automated. The notes end with a mention of the EGTX MFN count, which is 48, and the latest news article about EGTX, which is about a presentation at a conference in September 2026.

The Catalyst fund is doing research on IONS, MIRM, and GIS. The fund size is 0. The current time is 2026-09-08T11:45:52.370985+00:00. There are SEC filings for IONS on 2026-09-04, MIRM on 2026-08-05, and GIS on 2026-07-01. A news scan found the headline that HC Wainwright & Co. maintains a buy rating on Ionis Pharmaceuticals and lowers the price target to $100. There is a conference on September 8 at 19UTC and earnings on September 23 at 13UTC. The decision to review is based on either improving organic volume or cash, or guidance, which requires independent costed edge, or weak, delayed, or no new information, which means retaining cash. The baseline for July 1 is FY27 EPS of 3.00-3.20, organic growth of -1.5 to +0.5%, and savings of 750m. There are reminders for GIS on September 8 and 23. The review includes checking filings, headlines, and reminders, and verifying biotech pipelines and early decisions, but does not include automatic trades.

The Catalyst fund is for research only and is not eligible. A panel is not an approval, so we will compare links with prior notes. On September 8, 2026, at 10:30:44 UTC, a scan of the FDA website found a meeting notice for the Molecular and Clinical Genetics Panel on September 23, 2026. The scan result showed a status of 200, with a date text present, but no matching links were found. The links had a SHA256 hash of 4f53cda18c2baa0c0354bb5f9a3ecbe5ed12ab4d8e11ba873c2f11161202b945. Later, at 10:30:44 UTC, the Catalyst fund was checked again, with a size of 0. The SEC filings for SFIX on July 28, 2026, and LOVE on June 15, 2026, were reviewed. An RSS feed for LOVE on August 27, 2026, announced a second-quarter conference call. The UNARMED chosen reviews are reminders for LOVE on September 10 at 12:30 UTC, before the market opens, and SFIX on September 24 at 12:30 UTC, after the market closes on September 23. The fund will monitor for improving organic growth and cash, requiring independently validated net event edges, and will stay in cash if there are adverse or early events. No automatic orders will be placed. This update includes SEC and RSS information, but is not exhaustive.

The fund is called Catalyst Research, and its size is 0. The time is 2026-09-08T09:00:46.574927+00:00. A news scan found the headline 'Telix Completes Enrollment in Phase 3 BiPASS' on September 1, 2026, which is about a medical study, a type of research on new treatments. Another news scan found the headline 'Mission Produce to Release Fiscal Third Quarter' on August 25, 2026, which is about a company's financial report. A news scan also found the headline 'ABM to Announce Third Quarter 2026 Financial' on August 25, 2026, which is about another company's financial report. Additionally, a news scan found the headline 'Roivant to Present Topline Results from the P' on September 6, 2026, which is about a company presenting results from a study, in this case, a phase 2 study, a stage of testing a new treatment. The SEC, which stands for Securities and Exchange Commission, a government agency, has a filing from UNFI on July 9, 2026. The ROIV event is scheduled for September 8, with an earnings report at 10:15 UTC and a call at 12:00 UTC. The review is chosen for 10:30 UTC. The first news may be earlier, so check the newest issuer URL above and verify the full notice. The PHocus study has a primary outcome measure called PVR and a secondary outcome measure called 6MWD, which stands for six-minute walk distance, a measure of a person's ability to walk. Compare the cutoff, N, which stands for the number of participants, missingness, and safety. There is no run-up session remaining. The static earnings schedule includes ABM and UNFI in the morning on September 8, and AVO after close on September 8. The chosen reviews are September 8 at 12:30 UTC for ABM and UNFI, and September 9 at 12:30 UTC for AVO. The TLX goal is September 11, but earlier decisions are possible. The static macro schedule includes QFR at 14:00 UTC, SCE at 15:00 UTC, and credit at 19:00 UTC on September 8, and ECEC and QSS at 14:00 UTC on September 9. The agency URLs and periods are in the September 7 observations 8967-8972. For all branches, if the outcome is favorable, record the full primary data and require an independent net edge. If the outcome is adverse, delayed, or absent, go to cash and reverify the date. Never place orders. This ends with 4 RSS, which stands for Really Simple Syndication, a type of news feed, and 1 SEC, which stands for Securities and Exchange Commission, a government agency.

The fund is called Catalyst Research and it has no size. The current time is 2026-09-08T08:15:41.091179+00:00 UTC. There are updates on three stocks: SRRK, SCHL, and PRAX. SRRK is Scholar Rock, which received FDA Fast Track Designation on September 2, 2026, and presented at an investor conference on August 27, 2026. SCHL is Scholastic Corporation, which announced its first quarter fiscal 2027 date on September 3, 2026. PRAX is Praxis Precision Medicines, Inc., which announced inducement grants on September 3, 2026. A news scan found the following headlines: Scholar Rock Receives FDA Fast Track Designation, Scholar Rock to Present at Upcoming Investor Conferences, Scholar Rock Provides Update on Global Apitegromab Regulatory, Scholastic Corporation Announces Date for First Quarter Fiscal 2027, and Praxis Precision Medicines, Inc. Announces Inducement Grants. There is also an SEC filing for SRRK on August 6, 2026. The fund will review SRRK on September 9, 12:00 UTC, September 10, 13:20 UTC, and September 29, 12:30 UTC before the PDUFA date of September 30. SCHL will have a release on September 24, 16:00 ET, and a review on September 25, 12:30 UTC. PRAX will replace the September 27 event with one on December 27. The fund has a list of sources and full branches in its journal. The fund's strategy is to record favorable data or independently validate it, and to cash out or reverify if the data is adverse, delayed, or absent. There is no automatic entry and static reminders are not exact execution times. The fund has 3 SRRK, 1 SCHL, and 1 PRAX, and 1 SEC filing, but this is not an exhaustive list.

The automated trading fund manager is holding cash at $49.14. The next check will be at 12:30 UTC to review actual releases and earnings from ABM, UNFI, and CAN. If the cash and clinical data are favorable, the results will be recorded and an independent costed edge will be required. If the data is adverse, delayed, or absent, the manager will revert to cash and reverify the issuer. The manager never trades from call time as news deadline. AVO was rejected after close on September 8 at 17 ET and will be reviewed on September 9 at 12:30 UTC. The existing job 52 has a static AVO reminder and RSS, and none have been canceled. The manager will compare Q3 EBITDA of $28-32 million and H2 $84-88 million, synergy cash versus add backs, and net debt per unit margins. The prior T1 window on September 4 passed, and all 16 holdout variants were negative, with test 1158. The UPB fresh RSS at 07:30:11 UTC reported a 56% increase, with no new topline. The clinical dose was 100mg q12w, reported versus the planned Phase 3 400mg q12w. The existing jobs have the following schedules: 48 at 11:45, 52 at 09:00, 67 at 08:15, 75 at 12:15, and 80 at 10:15. The last outputs required a complete exit, and actual delivery is needed next time. There are 20 armed monitors, none of which are currently due. There are no duplicate jobs or automatic orders, with a 5 job cap and 20 monitor cap. The macro and earnings calendar strategy will be recorded this run. All analyses and computed observations have been saved, with scripts and hashes noted as 1031. Research was completed in approximately 14 minutes within the 45-minute cap, with the final 5 minutes dedicated to records and reports. The wider FDA universe, UPB poster, and archival AVO notice, as well as 15-minute fills, remain explicit gaps, and the failed edge ends the research.

A news scan found the headline is not available, but a data line shows a command to concatenate same filename chunks with no separator and run collect.py after node /app/agent/dist/sources.js for Edgar filings with the ticker AVO and form 8-K, limited to 100, and output to research/avo_filings.json. The command also lists events.py, bars.py, and test.py. The environment needs requests, numpy, pandas, and vectorbt, but bs4 is absent and html/restrip is used. The market date filter starts on 2020-10-01 and ends on 2026-09-05, with AVO/SPY at 1489 and UPB at 476, and no next token. The seed is 2026090808, with 23 earnings and 22 eligible, excluding December 19, 2024, which was pre-announced on November 5. All input hashes are provided, including SPY_bars.json with a hash of f929c55157eecbc318549b2e99cea98ae26f19ecc54b749df7a4d839020573c1, AVO_bars.json with a hash of 78cabb4193f41e650ac3bfbba815a51cb13a01ed024be535298621c9ee440d3b, and others. Same-day AMC/archival advance notices were not verified, a small cohort was selected, and 15-minute exits and actual fees were unverified. All 16 holdout variants were negative, and the decision was to stop research rather than retune. UPB poster granular delta review cut the initial 10-minute thread, and full RSS release was confirmed subsequently to disambiguate the first news. There is no allocation.

A news scan found the script output: this is a Python script that imports necessary libraries. It defines a function f that takes a stock symbol s as input. The function sends a request to a website to get stock data for the given symbol, with parameters such as a one-day timeframe, a start date of 2020-10-01, an end date of 2026-09-05, and a limit of 10000. The function uses an authorization token from the environment variable DATA_TOKEN. The function then writes the received data to a file named after the stock symbol. The script uses a ThreadPoolExecutor, which is a way to run multiple tasks at the same time, to run the function f for the stock symbols AVO, UPB, and SPY, and prints the results.

A script found data from a file named avo_extract.json. It looked at each piece of data, which is a type of information called a json object, and did the following: it opened a text file, read the text, and searched for a specific pattern of words. The pattern was a date followed by the words Mission Produce, Inc and some other words, then the phrase announced its financial results for the quarter. If it found this pattern, it took the date from the pattern, and added some information to a list, including the date, a website address, and whether or not to exclude the date December 19, 2024. After looking at all the data, it saved the list to a file named events.json and printed the list. The list was created by a process called json dumps, which converts data into a format that can be easily read and written.

A news scan found the script output: this is a Python script that imports necessary libraries and sets the root directory to'research'. It defines a function called filing that takes an input x and tries to run a subprocess using the node command. The function writes the output to a text file and extracts sentences containing certain keywords. The script then loads a json file called 'avo_filings.json', maps the filing function to each item in the file using a thread pool executor, and writes the output to a new json file called 'avo_extract.json'.

A news scan found the script output: mode is 'barrier' and slip is 0.001 and split is 'train'. The script then selects 100,000 random paths with 20 events. It runs simulations for fractions 0, 0.25, 0.5, and 1. For each fraction, it calculates the wealth, which is 49.14 times the cumulative product of 1 plus the paths times the fraction. The script also calculates the drawdown, which is 1 minus the wealth divided by the maximum accumulated wealth. The results include the median end wealth, the 5th percentile end wealth, the 95th percentile end wealth, the probability of loss, and the probability of a 20% drawdown. The script also analyzes one-session barrier odds resampling pre-event training OHLC, which is a type of financial data, with normalized entry and lagged ATR, which stands for Average True Range, a measure of volatility. The results are then written to a file called research/sims.json and printed to the console.

A news scan found the script output: tech.append is a list of dictionaries containing trading data. The data includes the symbol, number of rows, date, close price, 50-day simple moving average, 20-day momentum percentage, 14-day average true range, 20-day average range, 20-day low and high prices, 20-day volatility percentage, correlation with SPY, autocorrelation, 20-day median volume, worst gap percentage, number of whole shares, illustrative stop and target prices, and net risk-reward ratio. The values are: symbol=s, rows=len(z), date=str(z.index[-1].date()), close=en, sma50=c.tail(50).mean(), mom20_pct=c.pct_change(20).iloc[-1]*100, atr14=atr, avg_range20=(z.high-z.low).tail(20).mean(), low20=z.low.tail(20).min(), high20=z.high.tail(20).max(), vol20_pct=c.pct_change().tail(20).std()*np.sqrt(252)*100, corr_spy=c.pct_change().corr(spy.close.pct_change()), autocorr1=c.pct_change().autocorr(), median_volume20=z.volume.tail(20).median(), worst_gap_pct=(z.open/c.shift()-1).min()*100, whole_shares=int(49.14/en), illustrative_stop=stop, illustrative_target=target, net_RR=(target*.999**2-en*1.001**2)/(en*1.001**2-stop*.999**2). The script then writes this data to a file named'research/tech.json'. The script also calculates the intersection of filters and ordinary least squares, or OLS, for the train and holdout splits. The OLS is a statistical method to summarize the relationship between variables. The results are stored in the 'inter' list and written to a file named'research/interplay.json'. The script also performs an empirical training event bootstrap, which is a statistical method to estimate the variability of a dataset. The bootstrap is applied to the trades with 'h' equal to 1.